Gilead reports positive data from GS-6207 trial for HIV
GS-6207 is designed to disrupt HIV capsid, a multimeric shell that is essential to viral replication, at multiple stages throughout the viral life cycle. Credit: NIAID.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more